VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report report published on Thursday morning. The firm issued a sell rating on the stock.

VNRX has been the topic of several other reports. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital restated a “buy” rating and set a $5.00 target price on shares of VolitionRx in a report on Wednesday, January 8th.

VolitionRx Price Performance

Shares of VNRX opened at $0.63 on Thursday. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23. The firm has a fifty day simple moving average of $0.64 and a two-hundred day simple moving average of $0.66.

Insider Transactions at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds acquired 139,811 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were acquired at an average price of $0.57 per share, with a total value of $79,692.27. Following the completion of the purchase, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Guy Archibald Innes bought 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were acquired at an average cost of $0.57 per share, with a total value of $99,615.48. Following the purchase, the director now directly owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 358,266 shares of company stock valued at $204,212. Corporate insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC lifted its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the period. Geode Capital Management LLC owned approximately 0.79% of VolitionRx worth $439,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.